Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

62871.1 IP-LS

Project title

Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-	-

Inserted texts

Category	Text
Short description (German)	Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)
Short description (English)	Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids
Abstract (German)	Alentis Therapeutics AG is implementing unique anti-claudin 1 monoclonal antibodies as a novel approach for the treatment of liver fibrosis. This project aims at leveraging 3D-in vitro models to identify translational makers of target engagement.